Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing a strange hair loss pattern despite using dutasteride for 3 years and minoxidil with tretinoin for 1.5 years. They recently added microneedling and are considering a scalp biopsy to understand the cause.

The conversation is about a person experiencing significant hair loss in the donor area after a hair transplant, with others suggesting it might be shock loss. The person is taking oral minoxidil and dutasteride to help with the issue.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.

Astaxanthin may cause increased hair shedding, affecting even transplanted hair and eyebrows. The user has tried various treatments for androgenic alopecia, including minoxidil, finasteride, and RU58841.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

Adipose fat cells and stem cells may help treat hair loss by restoring the scalp's thickness. Treatments like NanoFat injections and Botox are discussed for their potential to promote hair growth.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Someone's brother tried Platelet-rich plasma (PRP) for hair loss; it had minimal effect on hair but improved skin appearance. Microneedling at home was suggested as a more sustainable alternative.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.

A 21-year-old experiencing itchy and burning scalp with hair loss was diagnosed with MPB and scalp inflammation. They were prescribed Ketoconazole, Prednisone, Clindamycin, and Finasteride, and are considering trying antihistamines, dietary changes, and "nopoo" to alleviate symptoms.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.

OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.

Hair loss discussion includes PRP procedures. Some say it's not worth the money.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

A user experienced hair loss after taking chromium and alpha lipoic acid supplements but stopped shedding after discontinuing them. They noticed thinning around the temples and started dermarolling.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.